8. ハンチントン病 Huntington disease Clinical trials / Disease details
臨床試験数 : 242 / 薬物数 : 205 - (DrugBank : 62) / 標的遺伝子数 : 85 - 標的パスウェイ数 : 159
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2021-003852-18-DE (EUCTR) | 06/05/2022 | 18/02/2022 | A Phase 2A study of PTC518 in patients with Huntington's Disease | A PHASE 2A, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY TO EVALUATE THE SAFETY AND EFFICACY OF PTC518 IN SUBJECTS WITH HUNTINGTON'S DISEASE - PIVOT-HD | Huntington’s disease MedDRA version: 20.0;Level: PT;Classification code 10070668;Term: Huntington's disease;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: PTC518 tablet 5 mg Product Code: PTC518 INN or Proposed INN: Not available Other descriptive name: PTC518 Product Name: PTC518 tablet 20 mg Product Code: PTC518 INN or Proposed INN: Not available Other descriptive name: PTC518 | PTC Therapeutics, INC | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 162 | Phase 2 | France;United States;Australia;Netherlands;Germany;United Kingdom | ||
| 2 | NCT05358717 (ClinicalTrials.gov) | April 25, 2022 | 27/4/2022 | A Study to Evaluate the Safety and Efficacy of PTC518 in Participants With Huntington's Disease (HD) | A Phase 2A, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PTC518 in Subjects With Huntington's Disease | Huntington Disease | Drug: PTC518;Drug: Placebo | PTC Therapeutics | NULL | Recruiting | 25 Years | N/A | All | 162 | Phase 2 | United States;Australia;France;Germany;Netherlands;United Kingdom |